- Home
- TOPS vs FGEN Comparison
TOPS vs FGEN Comparison
Compare TOPS & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TOPS
- FGEN
- Stock Information
- Founded
- TOPS 2000
- FGEN 1993
- Country
- TOPS Greece
- FGEN United States
- Employees
- TOPS N/A
- FGEN N/A
- Industry
- TOPS Marine Transportation
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- TOPS Consumer Discretionary
- FGEN Health Care
- Exchange
- TOPS Nasdaq
- FGEN Nasdaq
- Market Cap
- TOPS 27.2M
- FGEN 33.5M
- IPO Year
- TOPS 2004
- FGEN 2014
- Fundamental
- Price
- TOPS $6.14
- FGEN $7.58
- Analyst Decision
- TOPS
- FGEN Strong Buy
- Analyst Count
- TOPS 0
- FGEN 1
- Target Price
- TOPS N/A
- FGEN $250.00
- AVG Volume (30 Days)
- TOPS 63.0K
- FGEN 65.9K
- Earning Date
- TOPS 08-08-2025
- FGEN 08-05-2025
- Dividend Yield
- TOPS N/A
- FGEN N/A
- EPS Growth
- TOPS N/A
- FGEN N/A
- EPS
- TOPS 1.09
- FGEN N/A
- Revenue
- TOPS $86,127,000.00
- FGEN $6,996,000.00
- Revenue This Year
- TOPS $9.90
- FGEN N/A
- Revenue Next Year
- TOPS N/A
- FGEN N/A
- P/E Ratio
- TOPS $5.62
- FGEN N/A
- Revenue Growth
- TOPS 3.83
- FGEN N/A
- 52 Week Low
- TOPS $5.00
- FGEN $4.50
- 52 Week High
- TOPS $11.47
- FGEN $38.25
- Technical
- Relative Strength Index (RSI)
- TOPS 49.67
- FGEN 59.10
- Support Level
- TOPS $5.82
- FGEN $7.03
- Resistance Level
- TOPS $6.55
- FGEN $5.73
- Average True Range (ATR)
- TOPS 0.34
- FGEN 0.52
- MACD
- TOPS 0.04
- FGEN 0.30
- Stochastic Oscillator
- TOPS 69.66
- FGEN 85.45
About TOPS TOP Ships Inc.
TOP Ships Inc owns tanker vessels throughout the world. The Company is an international owner and operator of modern, fuel-efficient eco tanker vessels focusing on the transportation of crude oil, petroleum products (clean and dirty), and bulk liquid chemicals. It generates revenue from the Time Charter agreements.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.